<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">18970</article-id><article-id pub-id-type="doi">10.7554/eLife.18970</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-79819"><name><surname>Krall</surname><given-names>Elsa Beyer</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-7"/><xref ref-type="other" rid="par-8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-61476"><name><surname>Wang</surname><given-names>Belinda</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-79820"><name><surname>Munoz</surname><given-names>Diana M</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-61477"><name><surname>Ilic</surname><given-names>Nina</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-9"/><xref ref-type="other" rid="par-10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-79821"><name><surname>Raghavan</surname><given-names>Srivatsan</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-79822"><name><surname>Niederst</surname><given-names>Matthew J</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-79823"><name><surname>Yu</surname><given-names>Kristine</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-58641"><name><surname>Ruddy</surname><given-names>David A</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-61478"><name><surname>Aguirre</surname><given-names>Andrew J</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-11"/><xref ref-type="other" rid="par-12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-61479"><name><surname>Kim</surname><given-names>Jong Wook</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-79824"><name><surname>Redig</surname><given-names>Amanda J</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-79825"><name><surname>Gainor</surname><given-names>Justin F</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-58643"><name><surname>Williams</surname><given-names>Juliet A</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-17353"><name><surname>Asara</surname><given-names>John M</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-61480"><name><surname>Doench</surname><given-names>John G</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-61481"><name><surname>Janne</surname><given-names>Pasi A</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-79826"><name><surname>Shaw</surname><given-names>Alice T</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-79827"><name><surname>McDonald III</surname><given-names>Robert E</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-79828"><name><surname>Engelman</surname><given-names>Jeffrey A</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-79829"><name><surname>Stegmeier</surname><given-names>Frank</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-79830"><name><surname>Schlabach</surname><given-names>Michael R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-5558"><name><surname>Hahn</surname><given-names>William C</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2840-9791</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><institution>KSQ Therapeutics</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Department of Medical Oncology</institution>, <institution>Dana-Farber Cancer Institute</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Oncology Disease Area</institution>, <institution>Novartis Institute for Biomedical Research</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Department of Medicine</institution>, <institution>Massachusetts General Hospital</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution content-type="dept">Department of Medicine</institution>, <institution>Beth Israel Deaconess Medical Center</institution>, <addr-line><named-content content-type="city">Boston</named-content></addr-line>, <country>United States</country></aff><aff id="aff6"><institution>Broad Institute of Harvard and MIT</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-7876"><name><surname>McMahon</surname><given-names>Martin</given-names></name><role>Reviewing editor</role><aff><institution>University of Utah Medical Schoo</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>william_hahn@dfci.harvard.edu</email> (WH);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>01</day><month>02</month><year>2017</year></pub-date><volume>6</volume><elocation-id>e18970</elocation-id><history><date date-type="received"><day>21</day><month>06</month><year>2016</year></date><date date-type="accepted"><day>31</day><month>01</month><year>2017</year></date></history><permissions><copyright-statement>Â© 2017, Krall et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Krall et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-18970-v1.pdf"/><abstract><p>Inhibitors that target the receptor tyrosine kinase (RTK)/Ras/mitogen-activated protein kinase (MAPK) pathway have led to clinical responses in lung and other cancers, but some patients fail to respond and in those that do resistance inevitably occurs<sup>1-4</sup>. To understand intrinsic and acquired resistance to inhibition of MAPK signaling, we performed CRISPR-Cas9 gene deletion screens in the setting of BRAF, MEK, EGFR, and ALK inhibition. Loss of <italic>KEAP1</italic>, a negative regulator of NFE2L2/NRF2, modulated the response to BRAF, MEK, EGFR, and ALK inhibition in BRAF-, NRAS-, KRAS-, EGFR-, and ALK-mutant lung cancer cells. Treatment with inhibitors targeting the RTK/MAPK pathway increased reactive oxygen species (ROS) in cells with intact KEAP1, and loss of KEAP1 abrogated this increase. In addition, loss of KEAP1 altered cell metabolism to allow cells to proliferate in the absence of MAPK signaling. These observations suggest that alterations in the KEAP1/NRF2 pathway may promote survival in the presence of multiple inhibitors targeting the RTK/Ras/MAPK pathway.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>R01 CA130998</award-id><principal-award-recipient><name><surname>Hahn</surname><given-names>William C</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution>Dana-Farber Cancer Institute Hale Center for Pancreatic Cancer</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Aguirre</surname><given-names>Andrew J</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution>Perry S. Levy Endowed Fellowship</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Aguirre</surname><given-names>Andrew J</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution>Harvard Catalyst and Harvard Clinical and Translational Science Center</institution></institution-wrap></funding-source><award-id>UL1 TR001102</award-id><principal-award-recipient><name><surname>Aguirre</surname><given-names>Andrew J</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>U01 CA176058</award-id><principal-award-recipient><name><surname>Hahn</surname><given-names>William C</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>U01 CA199253</award-id><principal-award-recipient><name><surname>Hahn</surname><given-names>William C</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution>Hope Funds for Cancer Research</institution></institution-wrap></funding-source><award-id>Postdoctoral Fellowship HFCR-11-03-03</award-id><principal-award-recipient><name><surname>Krall</surname><given-names>Elsa Beyer</given-names></name></principal-award-recipient></award-group><award-group id="par-8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>Postdoctoral Fellowship F32 CA189306</award-id><principal-award-recipient><name><surname>Krall</surname><given-names>Elsa Beyer</given-names></name></principal-award-recipient></award-group><award-group id="par-9"><funding-source><institution-wrap><institution>Susan G. Komen Foundation</institution></institution-wrap></funding-source><award-id>Postdoctoral Fellowship PDF12230602</award-id><principal-award-recipient><name><surname>Ilic</surname><given-names>Nina</given-names></name></principal-award-recipient></award-group><award-group id="par-10"><funding-source><institution-wrap><institution>Terri Brodeur Breast Cancer Foundation</institution></institution-wrap></funding-source><award-id>Postdoctoral Fellowship</award-id><principal-award-recipient><name><surname>Ilic</surname><given-names>Nina</given-names></name></principal-award-recipient></award-group><award-group id="par-11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100001784</institution-id><institution>Pancreatic Cancer Action Network</institution></institution-wrap></funding-source><award-id>Samuel Stroum Fellowship</award-id><principal-award-recipient><name><surname>Aguirre</surname><given-names>Andrew J</given-names></name></principal-award-recipient></award-group><award-group id="par-12"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006293</institution-id><institution>American Society of Clinical Oncology</institution></institution-wrap></funding-source><award-id>Young Investigator Award</award-id><principal-award-recipient><name><surname>Aguirre</surname><given-names>Andrew J</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>William C Hahn, A consultant and receives research support from Novartis.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: Mice were maintained and handled in accordance with the Novartis Institutes for Biomedical Research (NIBR) Animal Care and Use Committee protocols and regulations.</p></fn></fn-group></sec><sec sec-type="supplementary-material"><supplementary-material><ext-link xlink:href="elife-18970-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>